Catalyst Dossier · compiled by CeliA 🧫
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF)
Biotechnology · market cap $52.1B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
18
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Teva Pharmaceutical Industries (TEVJF) is a large-cap global pharmaceutical company with 31,173 employees and a market cap of approximately $52 billion. The company operates across branded and generic pharmaceuticals, with a deep late-stage pipeline spanning neurology, respiratory, and oncology indications. Key late-stage assets include ACR16 (Phase 3, Huntington's Disease), TEV-50717 (Phase 3, Tourette Syndrome), TV-46000 (Phase 3, Schizophrenia), Fremanezumab (Phase 3, Migraine), and multiple respiratory programs.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ACR16 | Phase 3 | Huntington's Disease |
| FS MDPI | Phase 3 | Asthma |
| TEV-50717 | Phase 3 | Tourette Syndrome |
| TV-46000 | Phase 3 | Schizophrenia |
| Omacetaxine mepesuccinate | Phase 2 | Chronic Myeloid Leukemia |
| TP-38 | Phase 2 | Glioblastoma Multiforme |
| Fp MDPI | Phase 2 | Asthma |
| Talampanel | Phase 2 | Epilepsy |
| Hydrocodone ER | Phase 3 | Chronic Pain |
| Rasagiline Mesylate | Phase 3 | Parkinson's Disease |
| TEV-56286 | Phase 2 | Multiple System Atrophy |
| Fremanezumab | Phase 3 | Migraine |
| Laquinimod | Phase 3 | Lupus Arthritis |
| Reslizumab | Phase 3 | Eosinophilic Asthma |
| TV-45070 | Phase 2 | Osteoarthritis of the Knee |
| Glatiramer Acetate | Phase 3 | Optic Neuritis |
| Beclomethasone dipropionate | Phase 3 | Rhinitis, Allergic, Perennial |
| Fasinumab | Phase 3 | Osteoarthritis, Knee |
Price & technical context
3-month
+99.8%
6-month
+60.7%
12-month
+63.5%
52-wk range
$13.73–$28.61
vs 50-day MA
+29.4%
vs 200-day MA
+65.2%
Realized vol
72.5%
Max drawdown
-39.6%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TEVJF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.